Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome
- 26 June 2024 - 1 mins read
The purpose of the protocol is to assess the efficacy and safety of BIM 23A760 on patient’s overall satisfaction in terms of symptom relief (diarrhoea and/or flushes) in patients with carcinoid syndrome after 24 weeks of treatment.
26 June 2024
1 mins read
Which is the Best Dose of Dysport in Helping With Hip Pain for Children With Cerebral Palsy?
26 June 2024
1 mins read
Study to Assess Impact of Dysport Injections Early After Stroke on Upper Limb Spasticity Progression
26 June 2024
1 mins read
Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive Bladder
26 June 2024
1 mins read
Dysport® Pediatric Lower Limb Spasticity Follow-on Study
26 June 2024
1 mins read
Dysport® Adult Lower Limb Spasticity Follow-on Study
26 June 2024
1 mins read
Dysport® Pediatric Lower Limb Spasticity Study
26 June 2024
1 mins read
Dysport® Adult Lower Limb Spasticity Study
26 June 2024
1 mins read
Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines
26 June 2024
1 mins read
Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar Lines
26 June 2024
1 mins read